Wall Street analysts expect La Jolla Pharmaceutical (NASDAQ:LJPC) to post earnings of ($1.25) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for La Jolla Pharmaceutical’s earnings. The lowest EPS estimate is ($1.38) and the highest is ($1.10). La Jolla Pharmaceutical posted earnings of ($1.44) per share during the same quarter last year, which suggests a positive year over year growth rate of 13.2%. The firm is scheduled to announce its next earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($4.91) per share for the current fiscal year, with EPS estimates ranging from ($5.05) to ($4.74). For the next fiscal year, analysts expect that the company will post earnings of ($4.10) per share, with EPS estimates ranging from ($5.22) to ($2.38). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.05.

Several equities research analysts recently weighed in on LJPC shares. SunTrust Banks reissued a “buy” rating and set a $65.00 price target (down previously from $67.00) on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. Zacks Investment Research raised shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Wednesday, November 1st. HC Wainwright raised their price target on shares of La Jolla Pharmaceutical from $62.00 to $91.00 and gave the company a “buy” rating in a research report on Friday, December 29th. BidaskClub downgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 15th. Finally, Chardan Capital reissued a “buy” rating and set a $90.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. Three equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. La Jolla Pharmaceutical has a consensus rating of “Hold” and an average price target of $57.14.

In related news, Director Laura L. Douglass sold 10,000 shares of the firm’s stock in a transaction that occurred on Saturday, December 29th. The shares were sold at an average price of $32.32, for a total value of $323,200.00. Following the sale, the director now owns 6,000 shares in the company, valued at $193,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jennifer Carver bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 27th. The stock was bought at an average price of $33.22 per share, for a total transaction of $33,220.00. Following the acquisition, the chief operating officer now directly owns 4,500 shares of the company’s stock, valued at approximately $149,490. The disclosure for this purchase can be found here. 25.47% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc boosted its holdings in La Jolla Pharmaceutical by 11.6% in the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares during the last quarter. Jane Street Group LLC purchased a new stake in La Jolla Pharmaceutical in the third quarter worth approximately $200,000. Trexquant Investment LP purchased a new stake in La Jolla Pharmaceutical in the third quarter worth approximately $217,000. Voya Investment Management LLC purchased a new stake in La Jolla Pharmaceutical in the second quarter worth approximately $243,000. Finally, Nationwide Fund Advisors boosted its holdings in La Jolla Pharmaceutical by 20.4% in the second quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 1,688 shares during the last quarter.

Shares of La Jolla Pharmaceutical (LJPC) traded down $1.95 on Tuesday, hitting $28.51. 431,900 shares of the company traded hands, compared to its average volume of 670,000. The company has a market capitalization of $631.36, a P/E ratio of -5.59 and a beta of 1.63. La Jolla Pharmaceutical has a 12 month low of $16.71 and a 12 month high of $39.28.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/16/1-25-eps-expected-for-la-jolla-pharmaceutical-ljpc-this-quarter.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.